Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BNTC |
---|---|---|
09:32 ET | 2319 | 6.57 |
09:34 ET | 150 | 6.5901 |
09:48 ET | 500 | 6.72 |
09:52 ET | 292 | 6.95 |
10:32 ET | 118 | 6.67 |
10:39 ET | 288 | 6.9234 |
10:46 ET | 200 | 6.92 |
10:51 ET | 500 | 6.9048 |
11:09 ET | 400 | 6.8 |
11:11 ET | 100 | 6.8348 |
11:38 ET | 146 | 6.815 |
11:44 ET | 318 | 6.7894 |
12:02 ET | 1189 | 6.85 |
12:05 ET | 145 | 6.825 |
12:16 ET | 200 | 6.89 |
12:41 ET | 1824 | 7.04 |
12:56 ET | 1000 | 7.0184 |
01:15 ET | 100 | 7 |
01:26 ET | 200 | 7 |
01:46 ET | 1047 | 6.86 |
01:55 ET | 284 | 6.925 |
02:00 ET | 100 | 6.925 |
02:31 ET | 450 | 6.9986 |
02:51 ET | 1100 | 6.92 |
03:18 ET | 100 | 6.98 |
03:36 ET | 585 | 6.99 |
03:38 ET | 117 | 6.8621 |
03:39 ET | 500 | 6.99 |
03:45 ET | 400 | 7 |
03:50 ET | 500 | 7 |
03:52 ET | 400 | 7 |
03:54 ET | 495 | 7 |
03:56 ET | 1100 | 7 |
03:57 ET | 1191 | 7 |
03:59 ET | 2109 | 6.86 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Benitec Biopharma Inc | 57.2M | -0.6x | --- |
Oncolytics Biotech Inc | 78.9M | -3.5x | --- |
Reneo Pharmaceuticals Inc | 56.0M | -0.7x | --- |
OKYO Pharma Ltd | 47.3M | -0.1x | --- |
Intensity Therapeutics Inc | 55.5M | -4.7x | --- |
Gain Therapeutics Inc | 55.0M | -2.0x | --- |
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $57.2M |
---|---|
Revenue (TTM) | $61.0K |
Shares Outstanding | 8.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-10.90 |
Book Value | $0.12 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 938.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -35,560.66% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.